80 related articles for article (PubMed ID: 18318249)
1. [Clinical effects of intravenous ciprofloxacin on community-acquired pneumonia with positive Immunocard Mycoplasma test results].
Okimoto N; Nanba F; Kibayashi T; Kishimoto M; Yamato K; Kurihara T; Honda Y; Osaki K; Asaoka N
Nihon Kokyuki Gakkai Zasshi; 2008 Feb; 46(2):92-5. PubMed ID: 18318249
[TBL] [Abstract][Full Text] [Related]
2. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia.
Teh B; Grayson ML; Johnson PD; Charles PG
Clin Microbiol Infect; 2012 Apr; 18(4):E71-3. PubMed ID: 22284533
[TBL] [Abstract][Full Text] [Related]
3. [Testing for Mycoplasma pneumonia using the ImmunoCard Mycoplasma rapid test].
Okimoto N; Kibayashi T; Kishimoto M; Yamato K; Kurihara T; Mimura K; Honda Y; Osaki K; Asaoka N
Nihon Kokyuki Gakkai Zasshi; 2007 Mar; 45(3):233-6. PubMed ID: 17419434
[TBL] [Abstract][Full Text] [Related]
4. Adult community-acquired pneumonia caused by macrolide resistant Mycoplasma pneumoniae.
Isozumi R; Yoshimine H; Morozumi M; Ubukata K; Ariyoshi K
Respirology; 2009 Nov; 14(8):1206-8. PubMed ID: 19732389
[TBL] [Abstract][Full Text] [Related]
5. [The effect of intravenous ciprofloxacin for community acquired pneumonia in adults].
Fujita M; Ishibashi T; Hara N; Yoshida M; Yamada H;
Jpn J Antibiot; 2003 Aug; 56(4):289-93. PubMed ID: 14567253
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and ambulatory treatment of patients with community-acquired pneumonia: variability of complementary tests and study of the effectiveness of roxithromycin. Study Group on Ambulatory Treatment of Community-Acquired Pneumonia (NACTA)].
Rev Clin Esp; 1999 Nov; 199(11):700-4. PubMed ID: 10638232
[TBL] [Abstract][Full Text] [Related]
7. Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia.
Falguera M; Ruiz-González A; Schoenenberger JA; Touzón C; Gázquez I; Galindo C; Porcel JM
Thorax; 2010 Feb; 65(2):101-6. PubMed ID: 19703825
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and management of community-acquired pneumonia in adults.
Watkins RR; Lemonovich TL
Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
10. Chlamydia pneumoniae and Mycoplasma pneumoniae.
Blasi F; Tarsia P; Aliberti S; Cosentini R; Allegra L
Semin Respir Crit Care Med; 2005 Dec; 26(6):617-24. PubMed ID: 16388430
[TBL] [Abstract][Full Text] [Related]
11. Clinical effect of gatifloxacin, 200 mg daily, on bacterial community-acquired pneumonia in the elderly.
Okimoto N; Kibayashi T; Mimura K; Yamato K; Kurihara T; Honda Y; Osaki K; Asaoka N; Ohba H
J Infect Chemother; 2005 Dec; 11(6):274-7. PubMed ID: 16369733
[TBL] [Abstract][Full Text] [Related]
12. [Mycoplasma pneumonia in own clinical material].
Wolska-Goszka L; Petlak A; Siemińska A; Słomiński JM
Pol Merkur Lekarski; 1999 Sep; 7(39):102-4. PubMed ID: 10598483
[TBL] [Abstract][Full Text] [Related]
13. University-acquired pneumonia.
Allan RC; Moghal M; Wijesuriya V; Melzer M
Lancet Infect Dis; 2006 Mar; 6(3):184. PubMed ID: 16500601
[No Abstract] [Full Text] [Related]
14. [Positive phase periods of ImmunoCard Mycoplasma tests].
Okimoto N; Kibayashi T; Kishimoto M; Yamato K; Kurihara T; Mimura K; Honda Y; Osaki K; Asaoka N
Nihon Kokyuki Gakkai Zasshi; 2007 Jul; 45(7):543-5. PubMed ID: 17682464
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial treatment of community-acquired pneumonia in Hong Kong.
You JH; Lee VW; Au PS; Lee KK
Am J Health Syst Pharm; 2002 Sep; 59(18):1785-6. PubMed ID: 12298121
[No Abstract] [Full Text] [Related]
16. Mycoplasma pneumoniae and community-acquired pneumonia.
Dey AB; Chaudhry R; Kumar P; Nisar N; Nagarkar KM
Natl Med J India; 2000; 13(2):66-70. PubMed ID: 10835852
[TBL] [Abstract][Full Text] [Related]
17. Does sputum culture affect the management and/or outcome of community-acquired pneumonia?
Shariatzadeh MR; Marrie TJ
East Mediterr Health J; 2009; 15(4):792-9. PubMed ID: 20187530
[TBL] [Abstract][Full Text] [Related]
18. Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia.
Lui G; Ip M; Lee N; Rainer TH; Man SY; Cockram CS; Antonio GE; Ng MH; Chan MH; Chau SS; Mak P; Chan PK; Ahuja AT; Sung JJ; Hui DS
Respirology; 2009 Nov; 14(8):1098-105. PubMed ID: 19818051
[TBL] [Abstract][Full Text] [Related]
19. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.
Ramirez J; Unowsky J; Talbot GH; Zhang H; Townsend L
Clin Ther; 1999 Jan; 21(1):103-17. PubMed ID: 10090428
[TBL] [Abstract][Full Text] [Related]
20. [Study of administration times and clinical efficacy of carbapenems in the treatment of moderate community-acquired bacterial pneumonia].
Okimoto N; Yamato K; Kurihara T; Honda Y; Osaki K; Asaoka N; Fujita K; Ohba H
Nihon Kokyuki Gakkai Zasshi; 2004 Oct; 42(10):871-4. PubMed ID: 15565999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
